We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

107 hedge funds and large institutions have $62.4M invested in Aclaris Therapeutics in 2023 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 41 increasing their positions, 26 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 26

35% more call options, than puts

Call options by funds: $97K | Put options by funds: $72K

14.9% less ownership

Funds ownership: 98.84% → 83.94% (-15%)

22% less funds holding

Funds holding: 137 → 107 (-30)

55% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 53

87% less capital invested

Capital invested by funds: $480M → $62.4M (-$418M)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

Holders
107
Holders Change
-30
Holders Change %
-21.9%
% of All Funds
1.56%
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
24
Increased
41
Reduced
26
Closed
53
Calls
$97K
Puts
$72K
Net Calls
+$25K
Net Calls Change
-$6.32M

Top Buyers

1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$7.17M
2
Citadel Advisors
Citadel Advisors
Florida
+$6.2M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$5.71M
4
VCIM
Velan Capital Investment Management
Georgia
+$5.37M
5
TCM
Tang Capital Management
California
+$5.35M

Top Sellers

1
BI
BVF Inc
California
-$48.4M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$47.8M
3
RCM
RA Capital Management
Massachusetts
-$30.1M
4
FCMI
Foresite Capital Management IV
California
-$19.2M
5
GPP
Great Point Partners
Connecticut
-$11.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$6.2M +$909K +297,982 +5%
Citadel Advisors
2
Citadel Advisors
Florida
$5.66M +$6.2M +2,031,549 +61%
Vanguard Group
3
Vanguard Group
Pennsylvania
$4.96M +$4.15M +1,359,311 +40%
BCLSI
4
Bain Capital Life Sciences Investors
Massachusetts
$3.67M +$305K +100,000 +3%
Millennium Management
5
Millennium Management
New York
$3.65M +$4.61M +1,511,381 +77%
RSCM
6
Rock Springs Capital Management
Maryland
$3.15M -$2.93M -961,954 -24%
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$2.47M +$7.17M +2,351,407 New
Morgan Stanley
8
Morgan Stanley
New York
$2.05M +$773K +253,367 +15%
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$2.04M +$5.71M +1,873,000 +2,837%
VCIM
10
Velan Capital Investment Management
Georgia
$1.85M +$5.37M +1,761,595 New
TCM
11
Tang Capital Management
California
$1.84M +$5.35M +1,753,335 New
Renaissance Technologies
12
Renaissance Technologies
New York
$1.83M +$3.35M +1,098,780 +170%
Qube Research & Technologies (QRT)
13
Qube Research & Technologies (QRT)
United Kingdom
$1.76M +$5.13M +1,679,905 New
GCP
14
GSA Capital Partners
United Kingdom
$1.67M +$4.73M +1,550,026 +4,082%
Two Sigma Investments
15
Two Sigma Investments
New York
$1.54M +$4.39M +1,437,561 +5,550%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$1.49M +$3.89M +1,275,000 +873%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.46M +$172K +56,466 +4%
State Street
18
State Street
Massachusetts
$1.46M -$531K -174,069 -11%
MAM
19
Monaco Asset Management
Monaco
$1.03M +$2.99M +979,399 New
Deutsche Bank
20
Deutsche Bank
Germany
$981K +$2.38M +779,737 +505%
Jacobs Levy Equity Management
21
Jacobs Levy Equity Management
New Jersey
$786K +$1.75M +573,294 +327%
SB
22
Samsara BioCapital
California
$731K – – –
Fidelity Investments
23
Fidelity Investments
Massachusetts
$704K +$28.7K +9,414 +1%
Northern Trust
24
Northern Trust
Illinois
$693K +$812 +266 +0%
BCM
25
BML Capital Management
Indiana
$686K +$1.99M +653,107 New
1
2 3 4 5

ACRS Hedge Fund Activity: Q4 2023 in Review

107 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2023, worth a combined $62.4M — down 87% from $480M a quarter earlier.

Sellers outnumbered buyers: 53 funds closed out of ACRS and 24 opened new positions — a net loss of 29 holders — while 26 trimmed existing stakes and 41 added.

The largest buyer was Acadian Asset Management, opening a new position worth an estimated $7.17M. The largest seller was BVF Inc, exiting entirely with an estimated $48.4M sold.

  • 107 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2023, down from 137 in Q3 2023.
  • Funds reported $62.4M of Aclaris Therapeutics stock for Q4 2023, down 87% quarter-over-quarter.
  • 24 funds opened new Aclaris Therapeutics positions in Q4 2023 and 53 closed out, a net change of -29 holders.
  • The largest Aclaris Therapeutics buyer in Q4 2023 was Acadian Asset Management, an estimated $7.17M added.
  • The largest Aclaris Therapeutics seller in Q4 2023 was BVF Inc, an estimated $48.4M sold.

Based on aggregated 13F filings for Q4 2023.